Literature DB >> 27099586

Hepatosplenic T-Cell Lymphoma: A Population-Based Study Assessing Incidence and Association With Immune-Mediated Disease.

Michael Montgomery1, Marije M van Santen1, Bart J Biemond1, Robert H Diamond1, Steven T Pals1.   

Abstract

Hepatosplenic T-cell lymphoma (HSTCL) is a rare malignancy of unknown incidence that has been associated with immune-mediated disease. This study explored the incidence and patient characteristics of HSTCL in a population of 15.5 million over a 13-year period using a comprehensive national pathology database in The Netherlands (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief) with 100% capture. Twelve cases of HSTCL were identified during this period. The overall incidence of HSTCL in the Dutch population over this period was estimated at 0.06 per million inhabitant-years. All but 2 of the patients were adults at the time of diagnosis (median age, 34.5 years), and most patients died within a year of diagnosis. Three patients had a history of immune-mediated disease, 1 of whom was receiving azathioprine at the time of HSTCL diagnosis. Azathioprine as well as anti-tumor necrosis factor-α agents have been reported as possibly being associated with HSTCL. None of the 12 HSTCL patients had been treated with an anti-tumor necrosis factor-α agent.

Entities:  

Keywords:  Lymphoma; hepatosplenic; immune-mediated disease; immunodeficiency; immunosuppression

Year:  2015        PMID: 27099586      PMCID: PMC4836585     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  11 in total

1.  Aggressive peripheral T-cell lymphomas (specified and unspecified types).

Authors:  Kerry J Savage
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

2.  Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.

Authors:  Ann Corken Mackey; Lanh Green; Li-Ching Liang; Patricia Dinndorf; Mark Avigan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2007-02       Impact factor: 2.839

3.  Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression.

Authors:  Iwona Wlodarska; Nadine Martin-Garcia; Ruth Achten; Chris De Wolf-Peeters; Patrick Pauwels; Micheline Tulliez; Antoine de Mascarel; Josette Brière; Martine Patey; Anne Hagemeijer; Philippe Gaulard
Journal:  Genes Chromosomes Cancer       Date:  2002-03       Impact factor: 5.006

4.  Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas.

Authors:  W R Macon; N B Levy; P J Kurtin; K E Salhany; M Y Elkhalifa; T T Casey; F E Craig; C L Vnencak-Jones; M L Gulley; J P Park; J B Cousar
Journal:  Am J Surg Pathol       Date:  2001-03       Impact factor: 6.394

Review 5.  A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.

Authors:  David S Kotlyar; Mark T Osterman; Robert H Diamond; David Porter; Wojciech C Blonski; Mariusz Wasik; Sami Sampat; Manuel Mendizabal; Ming V Lin; Gary R Lichtenstein
Journal:  Clin Gastroenterol Hepatol       Date:  2010-10-01       Impact factor: 11.382

6.  Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin.

Authors:  C B Cooke; L Krenacs; M Stetler-Stevenson; T C Greiner; M Raffeld; D W Kingma; L Abruzzo; C Frantz; M Kaviani; E S Jaffe
Journal:  Blood       Date:  1996-12-01       Impact factor: 22.113

7.  Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.

Authors:  G S Falchook; F Vega; N H Dang; F Samaniego; M A Rodriguez; R E Champlin; C Hosing; S Verstovsek; B Pro
Journal:  Ann Oncol       Date:  2009-02-23       Impact factor: 32.976

8.  T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary.

Authors:  Lindsay A Schmidt; Megan S Lim
Journal:  J Hematop       Date:  2009-03-18       Impact factor: 0.196

Review 9.  Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?

Authors:  Joel R Rosh; Thomas Gross; Petar Mamula; Anne Griffiths; Jeffrey Hyams
Journal:  Inflamm Bowel Dis       Date:  2007-08       Impact factor: 5.325

Review 10.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

View more
  3 in total

Review 1.  Remicade® (infliximab): 20 years of contributions to science and medicine.

Authors:  Richard Melsheimer; Anja Geldhof; Isabel Apaolaza; Thomas Schaible
Journal:  Biologics       Date:  2019-07-30

2.  Hepatosplenic T cell lymphoma: a unifying entity in a patient with hemolytic anemia, massive splenomegaly, and liver dysfunction.

Authors:  Marianna Mavilia; Agnes McAuliffe; Safina Hafeez; Haleh Vaziri
Journal:  Clin J Gastroenterol       Date:  2018-05-15

3.  Survival Analysis of Hepatosplenic T Cell Lymphoma: A Population-Based Study Using SEER.

Authors:  Yajun Li; Kailin Chen; Chaohui Zuo; Ruolan Zeng; Yizi He; Xiaoyan Chen; Ling Xiao; Hui Zhou
Journal:  Int J Gen Med       Date:  2021-11-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.